Volume 33, Issue 4 (July 2022)
Studies in Medical Sciences 2022, 33(4): 291-305 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Sarebani H, Angaji S A, Beikzadeh B, Alibeik H, Roudi R, Narouie B. ASSOCIATION OF RS2107301 AND RS198977 POLYMORPHISMS WITH SUSCEPTIBILITY TO PROSTATE ADENOCARCINOMA IN IRANIAN POPULATION. Studies in Medical Sciences 2022; 33 (4) :291-305
URL: http://umj.umsu.ac.ir/article-1-5831-en.html
URL: http://umj.umsu.ac.ir/article-1-5831-en.html
Helia Sarebani 
, Seyed Abdolhamid Angaji * , Behnaz Beikzadeh , Hengameh Alibeik , Raheleh Roudi , Behzad Narouie
, Seyed Abdolhamid Angaji * , Behnaz Beikzadeh , Hengameh Alibeik , Raheleh Roudi , Behzad Narouie
Department of Cell and Molecular Biology, Faculty of Biological Sciences, Kharazmi University, Tehran, Iran (Corresponding Author) , Angaji@khu.ac.ir
Abstract: (1098 Views)
Background & Aims: Prostate cancer is the fifth most common cancers in men and the second most common cancer in terms of standardized age incidence (ASR 16.6) in Iranian population. The aim of this study was to evaluate the association of rs2107301 and rs198977 polymorphisms with susceptibility to prostate adenocarcinoma in Iranian population to use them as screening factors.
Materials & Methods: In this case-control study, a total of 178 people were studied in two groups of people with prostate cancer as case group and people without prostate cancer as control group. Tetra Primer ARMS PCR method was used to determine the genotype of each participant. By using SPSS v.25 software, statistical analyzes such as calculating the frequency of genotypes and examining the Hardy-Weirenberg equilibrium in two groups of cases and controls, examining the relationship between genotype and phenotype with a significant level (P-value < 0.05), evaluating dominant, recessive, incremental, and multiplicative models, and calculation of odds ratio and CI95% were calculated with logistic regression.
Results: There was no statistically significant difference between the genotypic distribution of rs2107301 (P-value = 0.521) and rs198977 (P-value = 0.181) in the case and control groups. However, we can use rs2107301 in the group with prostate adenocarcinoma to distinguish between positive and negative preneural Invasion forms.
Conclusion: The analyzes performed on rs2107301 and rs198977 polymorphisms for adenocarcinoma group in comparison with benign prostatic hyperplasia (BPH) showed that these two polymorphisms are not associated with prostate cancer.
Materials & Methods: In this case-control study, a total of 178 people were studied in two groups of people with prostate cancer as case group and people without prostate cancer as control group. Tetra Primer ARMS PCR method was used to determine the genotype of each participant. By using SPSS v.25 software, statistical analyzes such as calculating the frequency of genotypes and examining the Hardy-Weirenberg equilibrium in two groups of cases and controls, examining the relationship between genotype and phenotype with a significant level (P-value < 0.05), evaluating dominant, recessive, incremental, and multiplicative models, and calculation of odds ratio and CI95% were calculated with logistic regression.
Results: There was no statistically significant difference between the genotypic distribution of rs2107301 (P-value = 0.521) and rs198977 (P-value = 0.181) in the case and control groups. However, we can use rs2107301 in the group with prostate adenocarcinoma to distinguish between positive and negative preneural Invasion forms.
Conclusion: The analyzes performed on rs2107301 and rs198977 polymorphisms for adenocarcinoma group in comparison with benign prostatic hyperplasia (BPH) showed that these two polymorphisms are not associated with prostate cancer.
References
1. Moradi A, Zamani M, Moudi E. A systematic review and meta-analysis on incidence of prostate cancer in Iran. Health Promot Perspect 2019;9(2): 92-8. Available from: http: //dx.doi.org/10.15171/hpp.2019.13. [DOI:10.15171/hpp.2019.13] [PMID] [PMCID]
2. Culp MB, Soerjomataram I, Efstathiou JA, Bray F, Jemal A. Recent global patterns in prostate cancer incidence and mortality rates. Eur Urol 2020;77(1): 38-52. Available from: http: //dx.doi.org/10.1016/j.eururo.2019.08.005. [DOI:10.1016/j.eururo.2019.08.005] [PMID]
3. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71(3): 209-49. [DOI:10.3322/caac.21660] [PMID]
4. Roshandel G, Ghanbari-Motlagh A, Partovipour E, Salavati F, Hasanpour-Heidari S, Mohammadi G, et al. Cancer incidence in Iran in 2014: Results of the Iranian National Population-based Cancer Registry. Cancer Epidemiol 2019;61: 50-8. Available from: http: //dx.doi.org/10.1016/j.canep.2019.05.009. [DOI:10.1016/j.canep.2019.05.009] [PMID]
5. Sajadi A, Nooraie M, Ghorbani A, Alimohammadian M, Zahedi MJ, DarvishMoghadam S, et al. The incidence of prostate cancer in Iran: results of a population-based cancer registry. Arch Iran Med 2007;10(4): 481-5. [Google Scholar]
6. Beuten J, Gelfond JAL, Franke JL, Shook S, Johnson-Pais TL, Thompson IM, et al. Single and multivariate associations of MSR1, ELAC2, and RNASEL with prostate cancer in an ethnic diverse cohort of men. Cancer Epidemiol Biomarkers Prev 2010;19(2): 588-99. Available from: http: //dx.doi.org/10.1158/1055-9965.EPI-09-0864. [DOI:10.1158/1055-9965.EPI-09-0864] [PMID] [PMCID]
7. Schaid DJ. The complex genetic epidemiology of prostate cancer. Hum Mol Genet 2004;13(90001): R103-21. Available from: http: //dx.doi.org/10.1093/hmg/ddh072. [DOI:10.1093/hmg/ddh072] [PMID]
8. Schatten H. Brief overview of Prostate Cancer statistics, grading, diagnosis and Treatment Strategies. Adv Exp Med Biol 2018;1095: 1-14. Available from: http: //dx.doi.org/10.1007/978-3-319-95693-0_1. [DOI:10.1007/978-3-319-95693-0_1] [PMID]
9. Nam RK, Zhang WW, Trachtenberg J, Diamandis E, Toi A, Emami M, et al. Single nucleotide polymorphism of the human kallikrein-2 gene highly correlates with serum human kallikrein-2 levels and in combination enhances prostate cancer detection. J Clin Oncol 2003;21(12): 2312-9. Available from: http: //dx.doi.org/10.1200/JCO.2003.11.007. [DOI:10.1200/JCO.2003.11.007] [PMID]
10. Qian Y, Zhang L, Cai M, Li H, Xu H, Yang H, et al. The prostate cancer risk variant rs55958994 regulates multiple gene expression through extreme long-range chromatin interaction to control tumor progression. Sci Adv 2019;5(7): eaaw6710. Available from: http: //dx.doi.org/10.1126/sciadv.aaw6710. [DOI:10.1126/sciadv.aaw6710] [PMID] [PMCID]
11. Van Loo P, Nilsen G, Nordgard SH, Vollan HKM, Børresen-Dale AL, Kristensen VN, et al. Analyzing cancer samples with SNP arrays. Methods Mol Biol 2012;802: 57-72. Available from: http: //dx.doi.org/10.1007/978-1-61779-400-1_4 . [DOI:10.1007/978-1-61779-400-1_4] [PMID]
12. Albawardi A, Livingstone J, Almarzooqi S, Palanisamy N, Houlahan KE, Awwad AAA, et al. Copy number profiles of prostate cancer in men of Middle Eastern ancestry. Cancers 2021;13(10): 2363. Available from: http: //dx.doi.org/10.3390/cancers13102363. [DOI:10.3390/cancers13102363] [PMID] [PMCID]
13. Sävblom C, Halldén C, Cronin AM, Säll T, Savage C, Vertosick EA, et al. Genetic variation in KLK2 and KLK3 is associated with concentrations of hK2 and PSA in serum and seminal plasma in young men. Clin Chem 2014;60(3): 490-9. Available from: http: //dx.doi.org/10.1373/clinchem.2013.211219. [DOI:10.1373/clinchem.2013.211219] [PMID] [PMCID]
14. Bicak M, Wang X, Gao X, Xu X, Väänänen RM, Taimen P, et al. Prostate cancer risk SNP rs10993994 is a trans-eQTL for SNHG11 mediated through MSMB. Hum Mol Genet 2020;29(10): 1581-91. Available from: http: //dx.doi.org/10.1093/hmg/ddaa026. [DOI:10.1093/hmg/ddaa026] [PMID] [PMCID]
15. Klein RJ, Halldén C, Cronin AM, Ploner A, Wiklund F, Bjartell AS, et al. Blood biomarker levels to aid discovery of cancer-related single-nucleotide polymorphisms: kallikreins and prostate cancer. Cancer Prev Res (Phila) 2010;3(5): 611-9. Available from: http: //dx.doi.org/10.1158/1940-6207.CAPR-09-0206. [DOI:10.1158/1940-6207.CAPR-09-0206] [PMID] [PMCID]
16. Allemailem KS, Almatroudi A, Alrumaihi F, Makki Almansour N, Aldakheel FM, Rather RA, et al. Single nucleotide polymorphisms (SNPs) in prostate cancer: its implications in diagnostics and therapeutics. Am J Transl Res 2021;13(4): 3868-89. [PMCID]
17. Donkena KV, Young CYF. Vitamin d, sunlight and prostate cancer risk. Adv Prev Med 2011;2011: 281863. Available from: http: //dx.doi.org/10.4061/2011/281863. [DOI:10.4061/2011/281863] [PMID] [PMCID]
18. Kumawat G, Chaudhary V, Garg A, Mehta N, Talwar G, Yadav SS, et al. Association between vitamin D deficiency and prostate cancer: Prospective case-control study. J Clin Urol 2022;15(4): 309-14. Available from: http: //dx.doi.org/10.1177/2051415821993606. [DOI:10.1177/2051415821993606]
19. Tariq F, Khan MA, Shahzad S, Chaudhary WB, Arif A, Gharib G. Production of Remedial Proteins through Genetically Modified Bacteria. Adv Life Sci 2018;5(2): 37-45. [Google Scholar]
20. Zoued A, Brunet YR, Durand E, Aschtgen MS, Logger L, Douzi B, et al. Architecture and assembly of the Type VI secretion system. Biochim Biophys Acta 2014;1843(8): 1664-73. Available from: http: //dx.doi.org/10.1016/j.bbamcr.2014.03.018. [DOI:10.1016/j.bbamcr.2014.03.018] [PMID]
21. Moslemi E, Nouri M, Askari Gh. Effect of lycopene supplementation on infertility in men: A systematic review on clinical trial studies. Qom Univ Med Sci J 2018;12(12): 28-41. [DOI:10.29252/qums.12.12.28]
22. Mohsenzadegan, M., Z. Madjd, M. Asgari, M. Abolhasani, M. Shekarabi, J. Taeb and A. Shariftabrizi. "Reduced expression of NGEP is associated with high-grade prostate cancers: a tissue microarray analysis." Cancer Immunol Immunother 2013;62(10): 1609-8. [DOI:10.1007/s00262-013-1463-1] [PMID]
23. Hoseini M, Sazgar H, Zia Jahromi N. Study of the frequencies of rs137852579 in Androgen receptor coding gene in patients suffering from prostate cancer and theoretical study of the association of this polymorphism with drug resistance to treatment with enzalutamide. Cell Mol Biol 2019;10(37): 109-20. [Google Scholar]
24. Gudmundsson J, Sulem P, Rafnar T, Bergthorsson JT, Manolescu A, Gudbjartsson D, et al. Common sequence variants on 2p15 and Xp11. 22 confer susceptibility to prostate cancer. Nat Genet 2008;40(3): 281. [DOI:10.1038/ng.89] [PMID] [PMCID]
25. Špaková I, Rabajdová M, Dubayová K, Nagyová V, Pilátová MB, Mareková M. Development of novel parameter for monitoring of malignant melanoma progression. Pract Lab Med 2020;22(e00182): e00182. Available from: http: //dx.doi.org/10.1016/j.plabm.2020.e00182. [DOI:10.1016/j.plabm.2020.e00182] [PMID] [PMCID]
26. Shafai S, Moslemi E, Mohammadi M, Esfahani K, Izadi A. Expression of KLK2 gene in prostate cancer. Tehran Univ Med J 2018;75(10): 745-51. [Google Scholar]
27. Wang L. Correction: Association of polymorphism rs198977 in human kallikrein-2 gene (KLK2) with susceptibility of prostate cancer: A meta-analysis. PLoS One 2013;8(8). Available from: http: //dx.doi.org/10.1371/annotation/9e4eacfb-5de5-44f5-b027-b694f35e370e. [DOI:10.1371/annotation/9e4eacfb-5de5-44f5-b027-b694f35e370e]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
